Form 4: Longboard Pharmaceuticals Executive Exercises Options and RSUs in Merger with Lundbeck
SEC Form 4 Filing
Brandi Roberts, Executive VP and CFO of Longboard Pharmaceuticals, had her stock options and restricted stock units converted to cash as part of the company's merger with Lundbeck.
Summary
- This SEC Form 4 filing details the changes in beneficial ownership for Brandi Roberts, Executive VP and CFO of Longboard Pharmaceuticals, following the company's merger with H. Lundbeck A/S.
- The merger, completed on December 2, 2024, resulted in the cancellation of outstanding stock options and restricted stock units (RSUs) held by Roberts.
- Unvested stock options were accelerated and became fully vested, then converted to cash based on the difference between the merger price of $60.00 per share and the option's exercise price.
- Both vested and unvested RSUs were converted to cash at $60.00 per share, except for retention RSUs granted on October 25, 2024.
- Retention RSUs will be paid out based on the merger consideration, subject to continued service through October 25, 2025, or involuntary termination.
Sentiment
Score: 7
Explanation: The document is a factual report of a merger transaction and its impact on executive compensation. It is neither positive nor negative, but rather a neutral disclosure of events. The sentiment is therefore neutral to slightly positive as the merger has been completed.
Future Outlook
The document outlines the financial implications of the merger for the reporting person, with no forward-looking statements about the company's future performance.
Industry Context
This filing is a standard part of the merger process, reflecting the change in ownership and the resulting impact on executive compensation. It is common for executives to have their equity awards converted to cash in such transactions.
Comparison to Industry Standards
- The treatment of stock options and RSUs in this merger is consistent with standard practices in acquisitions, where equity awards are typically cashed out or converted to awards in the acquiring company.
- The $60.00 per share merger price is a key factor in determining the value of the cash payments to the executive.
- Similar transactions can be seen in the acquisition of other biotech companies, such as the acquisition of Immunomedics by Gilead, where stock options and RSUs were also converted to cash.
Stakeholder Impact
- Shareholders have received $60.00 per share as part of the merger.
- Employees with stock options and RSUs have received cash payments as a result of the merger.
- Executive officers with retention RSUs will receive payments based on continued service or involuntary termination.
Key Dates
| Date | Description |
|---|---|
| 10/14/2024 | Date of the Agreement and Plan of Merger between Longboard Pharmaceuticals and H. Lundbeck A/S. |
| 10/25/2024 | Date of grant for Retention Restricted Stock Units to certain employees, including executive officers. |
| 12/02/2024 | Date of the merger completion and conversion of stock options and RSUs to cash. |
| 02/07/2034 | Expiration date of one of the employee stock options. |
| 02/08/2032 | Expiration date of one of the employee stock options. |
| 02/08/2033 | Expiration date of one of the employee stock options. |
| 02/14/2031 | Expiration date of one of the employee stock options. |
| 10/25/2025 | Earliest vesting date for Retention RSUs, subject to continued service. |
Keywords
Merger, Stock Options, Restricted Stock Units, RSU, SEC Form 4, Longboard Pharmaceuticals, Lundbeck, Executive Compensation, Acquisition
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.